Dr Paul Wallace has been leading business development activities in both private and publicly listed companies for over 25 years. He has executed multiple partnership transactions with major pharma, regularly at the leading edge of deal trends. Successes include the hepatitis C protease inhibitor Olysio®, which became one of the fastest-launched drugs in the history of the industry. Prior to joining Constructive, Paul was Chief Business Officer at Mission Therapeutics Ltd and Executive Vice President at Medivir AB where he helped guide company growth from a research-focused model to a profitable, integrated company with commercial sales.  Paul had an earlier career in pharmaceutical research and carried out his PhD and post-doctoral studies in biochemistry at the University of Cambridge. He currently serves as the non-executive chairman of Semarion Ltd, a spin-out from the Cavendish Laboratory, University of Cambridge.